20
Participants
Start Date
May 18, 2022
Primary Completion Date
October 29, 2024
Study Completion Date
December 3, 2024
Debio 4126
Intramuscular (IM) injection
Sandostatin LAR
Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration
Somatuline ATG
Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration
Rigshospitalet, Endokrinologisk afdeling, Copenhagen
AP-HM - Hôpital de la Conception, Service d'Endocrinologie et Centre de Référence des Maladies Rares de l'hypophyse, Marseille
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan
Hospital Universitario Virgen del Rocio, Seville
Rabin Medical Center, Beilinson Hospital, Clalit Health Services by Rabin Medical Center, Beilinson Hospita, Petah Tikva
CHU Angers, Angers
Medicover Praxis fur Neuroendokrinologie, Munich
AP-HP Hopital Bicetre, Le Kremlin-Bicêtre
Sheba Medical Center, Endocrine institute, Ramat Gan
Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego w Katowicach, Katowice
Mazowiecki Szpital Brodnowski - Zespol Oddzialow Chorob Wewnetrznych, Endokrynologii i Diabetologii, Warsaw
Hospital de la Santa Creu i Sant Pau Barcelon, Barcelona
University Hospital Coventry, WISDEM Centre, UHCW NHS Trust, Coventry
Royal Free London NHS Foundation Trust, London
Lead Sponsor
Debiopharm International SA
INDUSTRY